06.04.2013 Views

toxicological profile for malathion - Agency for Toxic Substances and ...

toxicological profile for malathion - Agency for Toxic Substances and ...

toxicological profile for malathion - Agency for Toxic Substances and ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

a<br />

Key to<br />

figure<br />

96<br />

Species<br />

(Strain)<br />

Exposure/<br />

Duration/<br />

Frequency<br />

(Specific Route)<br />

Neurological<br />

Mouse 80 wk<br />

(B6C3F1)<br />

ad libitum<br />

(F)<br />

97 Mouse 18 mo<br />

(B6C3F1)<br />

Reproductive<br />

ad libitum<br />

(F)<br />

98 Mouse 80 wk<br />

(B6C3F1)<br />

Cancer<br />

ad libitum<br />

(F)<br />

99 Rat 2 yr<br />

(Fischer- 344)<br />

ad libitum<br />

(F)<br />

100 Mouse<br />

(B6C3F1)<br />

18 mo<br />

ad libitum<br />

(F)<br />

System<br />

Table 3-2 Levels of Significant Exposure to Malathion - Oral<br />

NOAEL<br />

(mg/kg/day)<br />

20.8 F<br />

Less Serious<br />

LOAEL<br />

Serious<br />

(mg/kg/day) (mg/kg/day)<br />

(continued)<br />

2980 F (generalized body tremors from<br />

week 71 to 79)<br />

143 M (24% <strong>and</strong> 44% inhibition of 1476 M (90% inhibition of plasma <strong>and</strong><br />

plasma <strong>and</strong> RBC cholinesterase<br />

activity, respectively)<br />

RBC cholinesterase activity)<br />

1490 F (cystic endometrial hyperplasia)<br />

868 F (CEL: increased incidence of<br />

combined hepatocellular<br />

adenoma <strong>and</strong> carcinoma)<br />

1476 M (CEL: increased incidence of<br />

combined hepatocellular<br />

carcinomas <strong>and</strong> adenomas)<br />

Reference<br />

Chemical Form<br />

NCI 1978<br />

Slauter 1994<br />

NCI 1978<br />

Daly 1996a<br />

Slauter 1994<br />

a The number corresponds to entries in Figure 3-2<br />

b Only this dose level, the lowest effect level, is plotted in Figure 3-2.<br />

c Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.02 mg/kg/day; The MRL was derived by dividing the NOAEL by an uncertainty factor of 10 to account <strong>for</strong><br />

human variability.<br />

d Used to derive a chronic-duration oral minimal risk level (MRL) of 0.02 mg/kg/day; The MRL was derived by dividing the NOAEL by an uncertainty factor of 100 (10 <strong>for</strong> animal to<br />

human extrapolation; 10 <strong>for</strong> human variability).<br />

e Differences in levels of health effects <strong>and</strong> cancer between males <strong>and</strong> females are not indicated in Figure 3-2. Where such differences exist, only the levels of effect <strong>for</strong> the most<br />

sensitive gender are presented.<br />

AchE = acetylcholinesterase; Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); (EEG) = electroencephalogram; (EMG) =<br />

electromyogram; Endocr = endocrine; (F) = feed; F = female; FSH = follicle stimulating hormone; (G) = gavage; gastro = gastrointestinal; gd = gestation day; (GO) = gavage in oil;<br />

(GW) = gavage in water; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-effect level; M = male; MCV = mean corpuscular volume; mg/kg/day =<br />

milligram/kilogram/day; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; RBC = red blood cell(s); Resp = respiratory; (W) = water; wk =<br />

week(s); x = times; yr = year(s)

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!